Wiley Launches 2026 Mass Spectra Database to Accelerate Identification of Seven Hundred New Synthetic Designer Drugs

Wiley releases 2026 Mass Spectra of Designer Drugs, adding 700+ new spectra to help forensic labs identify fentanyl analogs and novel psychoactive substances.

By: AXL Media

Published: Mar 10, 2026, 12:11 PM EDT

Source: The information in this article was sourced from Wiley

Strengthening the Front Lines of Forensic Drug Detection

As the global landscape of novel psychoactive substances (NPS) undergoes rapid and dangerous diversification, forensic laboratories require increasingly sophisticated tools to maintain public safety. Wiley, a global leader in research intelligence, has addressed this need with the 2026 release of "Mass Spectra of Designer Drugs." This essential database serves as the primary reference for Gas Chromatography-Mass Spectrometry (GC-MS) workflows, enabling analysts to rapidly identify unknown compounds that may be disguised or previously unrecorded in traditional medical literature.

Significant Expansion of Novel Psychoactive Substances

The 2026 update introduces more than 700 new mass spectra, representing a substantial increase in the database's analytical reach. Specifically, the release adds over 400 unique chemical entities, with a heavy focus on the most lethal categories of modern illicit drugs. These include emerging fentanyl variants, synthetic cannabinoids, and the increasingly prevalent nitazene opioids. By providing high-quality reference data for these specific metabolites and derivatives, Wiley ensures that toxicologists can confirm the presence of these substances with a high degree of certainty.

Comprehensive Spectral Intelligence for Global Laboratories

With this latest release, the total repository now encompasses 37,075 mass spectra and 27,900 unique chemical entities. This scale makes it the leading source of trusted spectral intelligence for forensic and analytical laboratories worldwide. Graeme Whitley, Wiley’s senior director of data science solutions, emphasized that the enhancements are designed to provide laboratories with the data necessary to keep pace with the emergence of harmful new substances that often appear in the market without warning.